Blog | InSphero
September 6, 2020

Understanding the Power of Islet Standardization for Diabetes Research

InSphero Scientist and islet biologist Joan Mir Coll discusses how multiparametic approaches for in vitro pancreatic research have the potential to revolutionize diabetes research. Over the past 3 decades, diabetes […]
July 2, 2020

A Novel Hanging Drop Organ-on-a-Chip System for Diabetes Drug Discovery

InSphero has a rich history of collaborating with researchers at ETH Zürich. The most recent example is a joint effort to develop and apply a novel microfluidic perifusion system to […]
June 12, 2020

Understanding Microfluidics: Toward Scalable
Body-on-a-Chip Systems

Microfluidics expert Olivier Frey explains how higher-order systems, such as multi-tissue Body-on-a-Chip networks, have the potential to faithfully replicate physiological interactions among different human organs–and what hurdles remain before this […]
May 1, 2020

The Future of High Content Analysis is 3D

InSphero recently had an opportunity to test the Yokogawa Platform for High Content Analysis (HCA) in our laboratories in Schlieren, Switzerland. Our goal was to see whether the Yokogawa instrument […]
May 1, 2020

Experimental Design Considerations for
NASH Drug Screening

An ongoing challenge in NASH Drug Discovery is selecting “fit for purpose” models for preclinical drug screening. InSphero liver expert Sue Grepper and Head of Liver Solutions Eva Thoma recently […]
March 13, 2020

InSphero launches new webinar series, starting with virtual SOT 2020 sessions

As the coronavirus epidemic prompts cancellations of scientific meetings around the world, we have been working on alternative methods to keep you informed of advances in 3D cell-based assay technology, […]
February 26, 2020

Are I-O therapeutics making traditional in vitro assays obsolete?

InSphero Oncology Experts Francesca Chiovaro and Irina Agarkova often collaborate closely with academic and pharma partners who are developing therapeutics that target the innate immune system. In this blog, Francesca shares […]
December 18, 2019

InSphero marks 10 years of Innovation in
3D cell-based assay technology

InSphero CEO Jan Lichtenberg muses about how far 3D cell technology has come since InSphero was founded in 2009 and shares the latest news about how our disruptive 3D technology […]
September 23, 2019

Can an in vitro NASH endpoint be truly predictive of the in vivo response?

Model systems, whether laboratory animals or human cell-based systems, have long been central to the discovery and development of new and better drugs for the treatment of human disease. But […]
July 30, 2019

Are Animal NASH models slowing us down?

InSphero Senior Application Scientist Sue Grepper explains why critical limitations of dietary and genetically modified rodent models for NASH may be slowing down drug discovery efforts in this blog.  She […]